Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical Trials Report for April 2014

    ... and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes ...

    Page last updated 04/18/2014 - 3:36pm.

  2. Clinical Trials Report for November 2014

    ... Syndromes Undergoing Monotherapy With Exjade (Deferasirox) The purpose of this trial is to examine the hematologic ... and chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration. This study is being ...

    Page last updated 10/30/2014 - 9:42am.

  3. Clinical Trials Report for October 2014

    ... Syndromes Undergoing Monotherapy With Exjade (Deferasirox) The purpose of this trial is to examine the hematologic ... and chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration. This study is being ...

    Page last updated 09/30/2014 - 10:05am.

  4. Clinical Trial Basics

    ... These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab ...

    Page last updated 01/20/2015 - 4:58pm.

  5. Clinical Trial Basics

    ... These include: decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab ...

    Page last updated 01/20/2015 - 4:46pm.